Using novel parenteral delivery systems, Isosceles Pharmaceuticals is developing a platform of proprietary options to treat acute pain. Parenteral delivery reduces hepatic exposure by avoiding first-pass metabolism and maximizes bioavailability by direct systemic delivery.
With nearly 80 million inpatient and outpatient surgical procedures performed in the U.S. annually, the treatment of acute postoperative pain remains an unmet need particularly with the current opioid crisis. Effective treatment of postoperative pain is important to patients, their doctors and to hospitals. Unrelieved pain can produce adverse effects on the cardiovascular system, pulmonary function, sleep, mood, return to normal physical function and even has the potential for deleterious effects on the immune system and can transition to chronic pain.